Cantor Fitzgerald Brokers Cut Earnings Estimates for AxoGen

AxoGen, Inc. (NASDAQ:AXGN - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of AxoGen in a report released on Wednesday, February 26th. Cantor Fitzgerald analyst R. Osborn now expects that the medical equipment provider will earn $0.07 per share for the year, down from their previous forecast of $0.19. The consensus estimate for AxoGen's current full-year earnings is ($0.29) per share.

Separately, Canaccord Genuity Group increased their price objective on AxoGen from $22.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, February 26th.

AxoGen Price Performance

NASDAQ AXGN traded down $0.12 during mid-day trading on Friday, hitting $19.89. The stock had a trading volume of 149,682 shares, compared to its average volume of 532,278. The firm's 50 day moving average is $17.75 and its 200 day moving average is $15.11. AxoGen has a twelve month low of $5.55 and a twelve month high of $21.00. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. The stock has a market capitalization of $875.32 million, a price-to-earnings ratio of -62.32 and a beta of 1.00.

Institutional Trading of AxoGen

Several large investors have recently added to or reduced their stakes in AXGN. Creative Planning grew its holdings in AxoGen by 152.2% in the 3rd quarter. Creative Planning now owns 29,790 shares of the medical equipment provider's stock valued at $418,000 after buying an additional 17,980 shares in the last quarter. Sentry Investment Management LLC grew its holdings in AxoGen by 9.3% in the 3rd quarter. Sentry Investment Management LLC now owns 17,368 shares of the medical equipment provider's stock valued at $243,000 after buying an additional 1,483 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in AxoGen in the 3rd quarter valued at $207,000. Primoris Wealth Advisors LLC purchased a new stake in AxoGen in the 3rd quarter valued at $207,000. Finally, Los Angeles Capital Management LLC purchased a new stake in AxoGen in the 3rd quarter valued at $279,000. 80.29% of the stock is currently owned by hedge funds and other institutional investors.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.